BeOne MedicinesBEIGF 61 EV-to-FCF is 25.73 as of Jul. 01, 2026. GuruFocus rates BEIGF with a GF Score™ of 61/100 and a GF Value™ of $27.70 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 331 Biotechnology companies, BeOne Medicines ranks worse than 62.24% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BeOne Medicines's Enterprise Value is $28,143 Mil.
BeOne Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $1,094 Mil. Therefore, BeOne Medicines's EV-to-FCF for today is 25.73.
The historical rank and industry rank for BeOne Medicines's EV-to-FCF or its related term are showing as below:
BEIGF'
s EV-to-FCF Range Over the Past 10 Years
Min: -151.73 Med: -9.71 Max: 222.9
Current: 25.73
During the past 13 years, the highest EV-to-FCF of BeOne Medicines was 222.90. The lowest was -151.73. And the median was -9.71.
BEIGF's EV-to-FCF is ranked worse than 62.24% of 331
companies
in the Biotechnology industry
Industry Median: 15.57
vs BEIGF: 25.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BeOne Medicines's PE Ratio (TTM) for today is calculated as:
BeOne Medicines's share price for today is $21.946.
BeOne Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BeOne Medicines EV-to-FCF Related Terms
BeOne Medicines EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeOne Medicines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's EV-to-FCF falls into.
BeOne Medicines's current Enterprise Value is $28,143 Mil.
BeOne Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,094 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (BEIGF) has a EV-to-FCF of 25.73 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #206 out of 331 companies in the Biotechnology industry, placing it in the top 62.2%.
Is BeOne Medicines' EV-to-FCF too high?
BeOne Medicines' current EV-to-FCF is 25.73. The Biotechnology industry median EV-to-FCF is 15.57. BeOne Medicines' value of 25.73 is 65.3% above this industry median. Based on the distribution chart, BeOne Medicines ranks #206 out of 331 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' EV-to-FCF compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #206 out of 331 companies for EV-to-FCF. This places BeOne Medicines in the lower half of its industry. The industry median EV-to-FCF is 15.57. BeOne Medicines' value of 25.73 is 65.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current EV-to-FCF of 25.73 is 65.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current EV-to-FCF is 25.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (BEIGF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.70, compared to a current price of $21.95 — trading 20.8% below its estimated fair value. The current EV-to-FCF is 25.73 and 65.3% above the Biotechnology industry median of 15.57. BeOne Medicines' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BeOne Medicines (BEIGF), the current EV-to-FCF is 25.73 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (BEIGF) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $21.95 is trading 20.8% below its estimated GF Value™ of $27.70.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for BEIGF:
EV-to-FCF: 25.73
GF Value™: $27.70 vs. price of $21.95 (20.8% below fair value)
Industry Position: 65.3% above the Biotechnology median (#206 of 331)
No single metric tells the full story. See the BEIGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
61GF Score
Get the complete analysis for BEIGF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEIGF has been successfully added to your 
